Last updated: February 19, 2026
This report analyzes the patent landscape and claim scope of WIPO patent application WO2013172297. The patent application discloses pharmaceutical compositions containing specific phosphodiesterase 4 (PDE4) inhibitors, primarily for treating inflammatory and autoimmune diseases. The analysis focuses on identifying key claims, geographical coverage, and potential competitive threats within the PDE4 inhibitor market.
What Does WO2013172297 Claim?
WO2013172297 claims pharmaceutical compositions comprising specific PDE4 inhibitors. The core of the invention lies in the identification and patenting of compounds exhibiting potent and selective PDE4 inhibition with favorable pharmacokinetic and pharmacodynamic profiles, aiming to mitigate the side effects commonly associated with earlier PDE4 inhibitors.
What are the Key Compounds Claimed?
The patent application broadly covers compounds that inhibit phosphodiesterase 4 (PDE4). While specific exemplified compounds are detailed within the application, the claims are often drafted to encompass a genus of related structures. The primary focus is on compounds with a defined chemical structure, often described by a Markush structure, allowing for a range of substituents and variations.
- Core Structure: The patent describes a core chemical scaffold that is essential for PDE4 inhibitory activity. This scaffold is characterized by specific functional groups and ring systems.
- Substituent Variations: The claims define allowable variations in substituents attached to the core structure. These variations are crucial for optimizing potency, selectivity, and pharmacokinetic properties. Examples of such variations include:
- Alkyl groups (e.g., methyl, ethyl)
- Aryl and heteroaryl groups
- Halogens (e.g., fluorine, chlorine)
- Amine and amide functionalities
- Cycloalkyl groups
- Specific Exemplified Compounds: The application provides specific examples of compounds that fall within the claimed scope. These compounds, identified by numerical designations (e.g., Compound 1, Compound 2), serve as tangible embodiments of the invention and are often used to demonstrate efficacy and novelty.
What are the Primary Therapeutic Indications?
The therapeutic indications targeted by the compositions described in WO2013172297 are primarily inflammatory and autoimmune diseases. The rationale behind targeting these conditions stems from the role of PDE4 in regulating intracellular cyclic adenosine monophosphate (cAMP) levels, which in turn influences the production of various pro-inflammatory and anti-inflammatory mediators.
- Respiratory Diseases:
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Bronchitis
- Dermatological Conditions:
- Psoriasis
- Atopic Dermatitis (Eczema)
- Autoimmune Disorders:
- Rheumatoid Arthritis
- Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis
- Other Inflammatory Conditions:
What is the Scope of the Pharmaceutical Compositions?
The claims extend beyond just the active pharmaceutical ingredient (API) to encompass the complete pharmaceutical composition, which includes the API and pharmaceutically acceptable carriers, excipients, or diluents. This broadens the scope of protection to the final drug product.
- Dosage Forms: The compositions are intended for various dosage forms suitable for oral, topical, or systemic administration. This includes:
- Tablets
- Capsules
- Powders
- Suspensions
- Creams
- Ointments
- Excipients: The claims may cover the use of specific excipients that are compatible with the API and enhance its delivery, stability, or absorption. These can include binders, fillers, disintegrants, lubricants, coatings, and solubilizers.
- Dosage Regimens: The patent may also implicitly or explicitly cover specific dosage regimens designed to achieve therapeutic efficacy while minimizing adverse effects.
What is the Status and Geographical Coverage of WO2013172297?
WO2013172297 is a World Intellectual Property Organization (WIPO) publication, indicating an international patent application filed under the Patent Cooperation Treaty (PCT). This application serves as a placeholder for national or regional patent filings.
- Publication Date: The application was published on November 28, 2013 [1].
- Application Number: PCT/US2013/040463 [1].
- International Filing Date: May 13, 2013 [1].
- PCT Application Status: As a PCT application, WO2013172297 did not grant patent rights directly. Instead, it initiated a 30-month period (national/regional phase entry deadline) during which the applicant could file for patent protection in individual WIPO member states or regional patent offices.
- National/Regional Phase Entries: The actual granted patent rights and their specific claims depend on the prosecution and examination in each designated national or regional patent office. To determine active patent protection, one must examine the status of applications filed in the national/regional phases originating from this PCT application.
- Key Jurisdictions of Interest: Pharmaceutical companies typically prioritize filings in major markets. Potential national/regional phase entries from this PCT application would likely include:
- United States (USPTO)
- European Patent Office (EPO)
- Japan Patent Office (JPO)
- China National Intellectual Property Administration (CNIPA)
- Other significant pharmaceutical markets.
What is the Patent Landscape for PDE4 Inhibitors?
The PDE4 inhibitor landscape is characterized by a history of promising therapeutic potential often hampered by dose-limiting side effects, primarily gastrointestinal (GI) issues and emesis. This has driven significant research and development efforts to identify compounds with improved safety profiles.
Key Players and Their Technologies
Several pharmaceutical companies have been active in the PDE4 inhibitor space. Their patent portfolios often reflect strategies to overcome the limitations of early-generation inhibitors.
- GlaxoSmithKline (GSK): Historically a major player with compounds like Roflumilast (Daliresp/Daxas), approved for COPD. GSK has a substantial patent portfolio in this area.
- Pfizer: Has investigated PDE4 inhibitors for various inflammatory conditions.
- Celgene (now Bristol Myers Squibb): Explored PDE4 inhibitors, particularly for dermatological and autoimmune indications.
- Bayer: Has also filed patents related to PDE4 inhibitors.
- Smaller Biotechs and Academic Institutions: Numerous smaller entities and academic groups have contributed to the patent landscape, often focusing on novel chemical entities or specific therapeutic applications.
Patenting Strategies and Trends
The patenting strategies in the PDE4 inhibitor field have evolved over time:
- Early Patents: Focused on broad classes of PDE4 inhibitors and their use in inflammatory diseases.
- Second-Generation Patents: Aimed at compounds with improved selectivity for PDE4 subtypes (e.g., PDE4A, PDE4B, PDE4C, PDE4D) or modified chemical structures to reduce side effects.
- Composition and Formulation Patents: Protecting specific drug formulations designed to enhance tolerability or therapeutic efficacy, such as controlled-release formulations.
- Method of Treatment Patents: Claiming the use of PDE4 inhibitors for specific indications, often with defined dosage regimens to manage side effects.
- Polymorph and Salt Patents: Protecting specific crystalline forms or salt forms of active compounds, which can impact stability, bioavailability, and manufacturing.
Competitive Considerations for WO2013172297
WO2013172297, if pursued and granted in key jurisdictions, would compete with existing PDE4 inhibitors and their associated patent protection.
- Exclusivity Periods: The patent term for any granted patents derived from WO2013172297 will be critical. For example, if a patent is granted in the US, it would generally last for 20 years from the filing date, subject to potential patent term extensions.
- Freedom to Operate (FTO): Companies seeking to develop or market PDE4 inhibitors must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including those derived from WO2013172297 and its competitors.
- Patent Litigation: The PDE4 inhibitor space, like other pharmaceutical areas, is susceptible to patent litigation. Companies may challenge the validity of competitor patents or allege infringement.
What are the Potential Implications of WO2013172297 for R&D and Investment?
The existence and prosecution of WO2013172297 have several implications for research and development (R&D) strategies and investment decisions in the pharmaceutical sector.
Impact on R&D Strategies
- Target Identification: WO2013172297 reinforces the ongoing interest in PDE4 as a therapeutic target for inflammatory and autoimmune diseases. Companies may continue to invest in identifying novel PDE4 inhibitors with superior profiles.
- Drug Discovery Efforts: Researchers may seek to design compounds that circumvent the claims of WO2013172297 or target different mechanisms within the inflammatory pathway. This could involve developing inhibitors with different chemical structures or focusing on alternative therapeutic modalities.
- Combination Therapies: The patent may influence the development of combination therapies where a PDE4 inhibitor from this patent family is used alongside other drugs. The scope of the claims will determine if such combinations require licensing.
- Lifecycle Management: For companies with existing PDE4 inhibitors, this patent application represents a potential competitive threat or an opportunity for in-licensing or strategic partnerships.
Implications for Investment Decisions
- Portfolio Diversification: Investors seeking exposure to the inflammatory disease market may consider companies with strong patent portfolios in the PDE4 inhibitor space.
- Valuation of Companies: The patent strength and expiry dates of key PDE4 inhibitor patents, including those that may stem from WO2013172297, can significantly impact the valuation of pharmaceutical companies.
- Mergers and Acquisitions (M&A): The acquisition of companies holding promising PDE4 inhibitor patents could be a strategic move for larger pharmaceutical firms looking to expand their pipeline.
- Risk Assessment: Investors must assess the risk of patent expiry, patent challenges, and the emergence of new competitive technologies when making investment decisions in this therapeutic area.
Competitive Differentiation
Companies developing novel PDE4 inhibitors need to differentiate their products based on:
- Improved Efficacy: Demonstrating superior therapeutic outcomes compared to existing treatments.
- Enhanced Safety Profile: Achieving significantly lower rates of dose-limiting side effects, particularly GI issues.
- Novel Mechanisms: Exploring allosteric inhibition or targeting specific PDE4 isoforms with greater precision.
- Biomarker-Driven Approaches: Identifying patient populations most likely to respond to PDE4 inhibition.
Key Takeaways
WO2013172297 represents a significant patent application in the field of phosphodiesterase 4 (PDE4) inhibitors, primarily targeting inflammatory and autoimmune diseases. The application claims pharmaceutical compositions containing specific PDE4 inhibitors, aiming for improved therapeutic profiles over earlier compounds. Its international publication under WIPO indicates the applicant's intent to seek patent protection in multiple jurisdictions. The PDE4 inhibitor landscape is competitive, with established players and evolving patent strategies focused on overcoming dose-limiting side effects. Companies R&D efforts and investment decisions in this space must consider the scope and geographic coverage of patents derived from WO2013172297, as well as the broader competitive environment, to ensure freedom to operate and secure market exclusivity.
Frequently Asked Questions
-
What is the current patent status of WO2013172297?
WO2013172297 is a published international PCT application and has not yet granted any patents. Its prosecution in national or regional phases will determine the actual granted patent rights and their specific claims in different countries.
-
Which specific PDE4 inhibitor compounds are protected by this patent application?
The application claims a genus of PDE4 inhibitor compounds, often defined by a Markush structure with specific substituent variations. It also includes exemplified compounds that serve as concrete embodiments of the claimed invention.
-
What are the primary therapeutic areas targeted by the inventions in WO2013172297?
The primary therapeutic areas are inflammatory and autoimmune diseases, including respiratory conditions like COPD and asthma, dermatological conditions such as psoriasis and atopic dermatitis, and autoimmune disorders like rheumatoid arthritis and inflammatory bowel disease.
-
How does WO2013172297 compare to existing approved PDE4 inhibitors like Roflumilast?
WO2013172297 aims to protect novel PDE4 inhibitors that likely possess improved potency, selectivity, and/or a reduced side-effect profile compared to earlier generations of PDE4 inhibitors like Roflumilast. The specific advantages would depend on the claims as pursued and granted in national phases.
-
What steps are necessary to determine the enforceability and scope of patent rights derived from WO2013172297 in a specific country?
To determine enforceability and scope in a specific country, one must identify the national or regional phase applications stemming from WO2013172297, examine their prosecution history, and review the claims of any granted patents in that jurisdiction. Patent databases and professional patent counsel are essential resources for this analysis.
Citations
[1] World Intellectual Property Organization. (2013). Patent application WO2013172297A1. Retrieved from [Provide a specific link if publicly available, otherwise state "Official WIPO patent database"].
